Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.15 per share.
For the full year, analysts predict revenues of $ 369.15 million, while looking forward to income of $ 0.55 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 360.00 million ~ $ 380.00 million
Click Here For More Historical Outlooks Of Ironwood Pharmaceuticals, Inc.
Previous Quarter Performance
Ironwood Pharmaceuticals, Inc. unfold income for the second quarter of $ 0.16 per share, from the revenue of $ 89.43 million. The quarterly earnings extended 60.00 percent while revenues shrunk 12.51 percent compared with the same quarter last year.
The consensus estimates are income of $ 0.09 per share from $ 86.24 million in revenue. The bottom line results beat street analysts by $ 0.07 or 77.78 percent, at the same time, top line results outshined analysts by $ 3.19 million or 3.70 percent.
Stock Performance
Shares of Ironwood Pharmaceuticals, Inc. traded up $ 0.33 or 3.32 percent on Wednesday, reaching $ 10.26 with volume of 3.34 million shares. Ironwood Pharmaceuticals, Inc. has traded high as $ 10.80 and has cracked $ 9.94 on the downward trend
The closing price of $ 10.26, representing a 24.28 % increase from the 52 week low of $ 7.99 and a 29.57 % decrease over the 52 week high of $ 14.10.
The company has a market capital of $ 1.64 billion and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Recent Analyst recommendations
- On 30th September 2020, downgraded by Wells Fargo & Co to Equal-Weight from Overweight rating.
Conference Call
Ironwood Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.ironwoodpharma.com
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. The company pipeline products also include olinciguat, an oral and once-daily vascular sGC stimulator, which is in Phase II trials for the treatment of patients suffering from sickle cell diseases; praliciguat, an oral, once daily systemic sGC stimulator that is in Phase II trials for the treatment of heart failure and for diabetic nephropathy; IW 6463, a central nervous system penetrant oral sGC stimulator in clinical development for serious neurodegenerative diseases; and two organ targeted programs for the treatment of liver and lung.
